Epstein-Barr Virus and Human Disease • 1988

1. Front Matter

   Pages i-xxvii

   PDF

2. Cellular and Molecular Biology of EBV

   1. Front Matter

      Pages 1-1

      PDF

   2. Epstein-Barr Virus Transformation of B Lymphocytes: Molecular Pathogenesis

      • David Liebowitz, Elliott Kieff, Jeffery Sample, Mark Birkenbach, Fred Wang

      Pages 3-15

      PDF

   3. Role of The Zebra Protein in the Switch Between Epstein-Barr Virus Latency and Replication

      • G. Miller, N. Talyor, J. Countryman, C. Rooney, D. Katz, J. Kolman et al.

      Pages 17-35

      PDF

   4. DNA:EBMA-1 Interactions and Latency of Epstein-Barr Virus

      • R. F. Ambinder, W. A. Shah, E. D. Fixman, B. C. Lambe, D. R. Rawlins, G. S. Hayward et al.

      Pages 37-42

      PDF

   5. The EBV DR Enhancer Contains two Functionally Different Domains: A and B.

      • Anna Chevallier Greco, H. Gruffat, E. Manet, Alain Sergeant

      Pages 43-47

      PDF

   6. Identification of the Gene Product Encoded by the Notl Repeats of the EBV Genome

      • M. Nübling, N. Müller-Lantzsch

      Pages 49-53

      PDF

   7. Effect of the BZLF1 Transactivator on Different Classes of EBV Promoters

      • Shannon Kenney, James Kamine, Elizabeth Holley-Guthrie, Jung-Chung Lin

      Pages 55-60

      PDF

   8. EBNA Expression and CpG Methylation of Viral DNA in EBV Associated Tumours

      • M. J. Allday, D. Kundu, B. E. Griffin

      Pages 61-62

      PDF

   9. Transcription and Protein Expression Pattern of EBV in Freshly Infected Lymphoid Cells

      • Ulrike Leser, Fritz Schwarzmann, Manfred Marschall, Hans Wolf

      Pages 63-67

      PDF

   10. Characterization of a cDNA of Epstein-Barr Virus DNase Gene

       • Mei-Ru Chen, Tswey-Ying Hsu, Jen-Yang Chen, Czau-Siung Yang

       Pages 69-74

       PDF

   11. The 5’Flanking Region of the Gene for EBNA2 Contains a Cell Type Specific cis-Acting Regulatory Element that Activates Transcription in Transfected B-Cells

       • A. Ricksten, A. Olsson, T. Andersson, L. Rymo

       Pages 75-78

       PDF

   12. Establishment and Characterization of a Tumor Cell Line from Nasopharyngeal Carcinoma Tissue

       • Y.-S. Chang, S.-Y. Lin, P.-F. Lee, H.-C. Chung, M.-S. Tsai

       Pages 79-82

       PDF

3. Molecular Pathobiology of EBV Infections

   1. Front Matter

      Pages 83-83

      PDF

   2. EBV DNA Structure and Expression in EBV-Induced Proliferations

      • Nancy Raab-Traub, Kevin Gilligan, Hiroshi Sato, Kathryn Flynn, Sharon Neese Edmiston, Jian-Jing Chen

      Pages 85-97

      PDF

   3. The Role of Differentially Expressed EB-Viral and Cellular Genes for Development of Virus-Related Tumors and Possibilities of the Control of These Diseases

      • Hans Wolf, Wolfgang Jilg, Christine Markert, Susanne Modrow, Christian Zietz, Eberhard Wilmes

      Pages 99-103

      PDF

   4. Detection of Proteins Binding to the EBV EBNA-2 Promoter

      • Jung-Chung Lin, Shannon Kenney, Joseph S. Pagano

      Pages 105-112

      PDF

   5. Anti EBNA-1 Protein Induced with TPA

      • L. T. Wen, A. Tanaka, M. Nonoyama

      Pages 113-118

      PDF

   6. Characterization of the EBV Alkaline Exonuclease Expressed in a Recombinant Prokaryotic System

      • E. Littler, S. A. Baylis, D. J. Purifoy

      Pages 119-124

      PDF

   7. Immunocytochemistry of EBV Envelope Glycoproteins on Freeze-Fractured Nuclear Membranes of Virus Producer Cells

      • M. R. Torrisi, M. Cirone, A. Pavan, C. Zompetta, G. Barile, L. Frati et al.

      Pages 125-130

      PDF

Epstein-Barr virus (EBV) is one of the most widespread human viruses, with over 80% of the general population exposed by young adulthood, as determined by antibody studies. Initial infection usu­ ally occurs during childhood or the teenage years. It is clear that, de­ pending on the age of the recipient, clinical manifestations of the primary infection can vary. It has been known for 20 years that EBV is the etiologic agent of acute infectious mononucleosis (IM) and is also closely associated with African Burkitt's lymphoma (BL) and naso­ it is a pharyngeal carcinoma (NPC). There is increasing evidence that factor in the etiology of B-celllymphomas, which arise at a high fre­ quency in immunodeficient populations. EBV may also contribute to the development of autoimmune disease. Thus, this virus continues to attract world-wide attention. The major target cell for EBV infection has now been conclusively identified as the complement receptor-type 2 (CR2), the Cd/Cdg 3 3 receptor on B lymphocyte. It is apparent, however, that other cells also can become infected by EBV, such as epithelial cells in the parotid gland and other epithelial cells in the upper respiratory tract. This might help account for the EBV-assodated carcinomas of the upper respiratory tract. The first in a series of international symposia on EBV -associated diseases focused primarily on Burkitt's-type lymphomas or on NPC (Kyoto 1977; Dusseldorf 1980; Kuala Lumpur 1982) and emphasized mainly the clinical elements of these diseases. Subsequent symposia (Loutraki, 1984; St.

• DNA
• Promoter
• cell lines
• gene expression
• genes
• molecular biology
• phorbol ester
• transcription

• National Cancer Institute, Bethesda, USA

  Dharam V. Ablashi

• Universitá “La Sapienza,”, Roma, Italy

  Alberto Faggioni

• University of Cologne, Cologne, West Germany

  Gerhard R. F. Krueger

• University of North Carolina, Chapel Hill, USA

  Joseph S. Pagano

• Georgetown University Medical School, USA

  Gary R. Pearson

Policies and ethics